Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

IMMX

Immix Biopharma Inc

May 01 • 04:00PM ET

2.17

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFUS DCOR

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	47.54%	Shs Outstand	19.92M	Perf Week	1.88%
Market Cap	57.29M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.45%	Shs Float	13.85M	Perf Month	-26.19%
Income	-15.43M	PEG	-	EPS next Q	-	Inst Own	8.67%	Short Float	2.53%	Perf Quarter	-43.19%
Sales	0.00M	P/S	-	EPS this Y	-24.00%	Inst Trans	19.81%	Short Ratio	1.38	Perf Half Y	-34.44%
Book/sh	0.82	P/B	2.64	EPS next Y	-8.60%	ROA	-88.57%	Short Interest	0.35M	Perf Year	-24.13%
Cash/sh	0.66	P/C	3.27	EPS next 5Y	-	ROE	-104.35%	52W Range	1.40 - 7.75	Perf YTD	-68.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.30%	ROI	-94.03%	52W High	-72.00%	Beta	0.24
Dividend TTM	-	Quick Ratio	5.32	Sales past 5Y	0.00%	Gross Margin	-	52W Low	55.00%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	5.32	EPS Y/Y TTM	-48.76%	Oper. Margin	0.00%	RSI (14)	34.34	Volatility	12.75% 11.61%
Employees	17	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	11.04%	Payout	-	Rel Volume	0.22	Prev Close	2.17
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	253.41K	Price	2.17
SMA20	-13.51%	SMA50	-24.33%	SMA200	-38.28%	Trades		Volume	55,808	Change	0.00%

Apr-29-24 02:50PM	Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment (MT Newswires)
09:39AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma (GlobeNewswire)
Apr-18-24 09:37AM	Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States (GlobeNewswire) -11.60%
09:32AM	Immix Biopharma on Track to Dose NXC-201 Patients in United States (GlobeNewswire)
Apr-15-24 09:36AM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
07:53AM	Loading…
Apr-02-24 07:53AM	IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 (InvestorPlace)
Mar-20-24 09:46AM	Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial (GlobeNewswire)
Mar-05-24 09:35AM	Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative (GlobeNewswire) -8.06%
Feb-21-24 09:31AM	Immix Biopharma 12 Month Review Progress Update (GlobeNewswire)
Feb-08-24 04:45PM	Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock (GlobeNewswire) +6.60%
Feb-07-24 09:37AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis (GlobeNewswire) +7.07%
Feb-05-24 10:30PM	Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock (GlobeNewswire) -19.89%
03:20PM	Immix Biopharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-24-24 08:35AM	Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products (GlobeNewswire)
Jan-04-24 09:34AM	Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board (GlobeNewswire)
09:39AM	Loading…
Dec-18-23 09:39AM	Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board (GlobeNewswire) -8.94%
Dec-11-23 09:36AM	Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 (GlobeNewswire)
Nov-30-23 09:46AM	Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:50AM	What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' (Zacks) +5.39%
Nov-22-23 11:10AM	Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down (Zacks) +5.01%
09:19AM	Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
Nov-21-23 09:46AM	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing (GlobeNewswire)
Nov-06-23 09:18AM	Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire) +20.73%
09:12AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire)
08:40AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients (GlobeNewswire)
Oct-31-23 09:55AM	Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.37%
Oct-26-23 08:58AM	Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board (GlobeNewswire)
Oct-16-23 09:05AM	Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Oct-03-23 09:14AM	Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting (GlobeNewswire) +5.31%
Oct-02-23 08:06AM	Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma (GlobeNewswire) +26.61%
12:04PM	Loading…
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-21-23 08:55AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis (GlobeNewswire) +15.38%
Sep-19-23 09:10AM	Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +24.15%
Sep-15-23 01:18PM	Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX) (GuruFocus.com) +5.12%
Sep-07-23 10:38AM	The 3 Best Speculative Stocks to Buy Now: September 2023 (InvestorPlace)
08:41AM	Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference (GlobeNewswire)
Sep-01-23 08:39AM	Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board (GlobeNewswire) +12.81%
Aug-23-23 08:37AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma (GlobeNewswire) +11.11%
Aug-18-23 09:20AM	Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board (GlobeNewswire) +6.13%
Aug-16-23 09:05AM	Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) (GlobeNewswire)
Jul-25-23 08:42AM	Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting (GlobeNewswire)
Jul-17-23 09:37AM	Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial (GlobeNewswire) -6.11%
Jul-10-23 09:47AM	Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Jun-26-23 09:49AM	Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial (GlobeNewswire) -6.90%
Jun-22-23 09:53AM	Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors (GlobeNewswire)
Jun-20-23 09:45AM	Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors (GlobeNewswire) +8.11%
Jun-16-23 09:43AM	Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors (GlobeNewswire) -5.93%
Jun-14-23 07:30AM	Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program (GlobeNewswire)
Jun-12-23 09:49AM	Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors (GlobeNewswire)
May-26-23 09:53AM	Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +9.38%
May-22-23 01:48PM	Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis (Benzinga) +6.71%
08:31AM	We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-21-23 04:05PM	Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
04:00PM	Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
May-04-23 12:30PM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
May-03-23 04:42PM	What's Going On With Immix Biopharma Stock Today (Benzinga)
08:00AM	Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab (GlobeNewswire)
Apr-26-23 05:30PM	Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris (GlobeNewswire)
Apr-04-23 08:00AM	Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting (GlobeNewswire) -7.45%
Mar-31-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells (GlobeNewswire) +5.81%
Mar-23-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential (GlobeNewswire) -7.94%
Mar-10-23 07:45PM	Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank (GlobeNewswire) -7.69%
Mar-06-23 08:00AM	ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14 (GlobeNewswire)
Feb-27-23 08:45AM	Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission (GlobeNewswire)
Feb-15-23 08:30AM	Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S. (GlobeNewswire)
Feb-09-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting (GlobeNewswire) -16.59%
Feb-07-23 08:00AM	Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer (GlobeNewswire) -8.01%
Jan-13-23 08:00AM	Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
Jan-06-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached (GlobeNewswire) -8.24%
Dec-28-22 08:00AM	Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting (GlobeNewswire) +8.50%
Dec-20-22 08:00AM	Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire) -5.08%
Dec-19-22 08:00AM	ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors (GlobeNewswire)
Dec-14-22 12:43PM	Why Immix Biopharma Shares Are Surging Today? (Benzinga) +23.29%
08:00AM	Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) (GlobeNewswire)
Dec-13-22 08:00AM	Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
05:06AM	We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely (Simply Wall St.)
Dec-12-22 08:00AM	ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing (GlobeNewswire) +7.91%
Nov-11-22 08:00AM	Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher (GlobeNewswire) +16.67%
Oct-25-22 08:00AM	Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26 (GlobeNewswire)
Oct-18-22 08:00AM	ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site (GlobeNewswire)
Sep-07-22 12:05PM	ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials (GlobeNewswire)
Aug-23-22 06:36AM	Insiders who bought in the last 12 months lose an additional US$175k as Immix Biopharma, Inc. (NASDAQ:IMMX) drops to US$28m (Simply Wall St.)
Aug-01-22 10:10AM	10 Best Penny Stocks to Buy and Hold According to Reddit (Insider Monkey)
May-21-22 08:26AM	We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth (Simply Wall St.)
May-20-22 10:19AM	ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug (Benzinga) +30.06%
08:47AM	ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study (GlobeNewswire)
May-09-22 08:00AM	Immix Biopharma Announces Share Repurchase Program (GlobeNewswire)
Apr-05-22 09:30AM	ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022 (GlobeNewswire) -22.01%
Mar-16-22 10:13AM	Multiple insiders bought Immix Biopharma, Inc. (NASDAQ:IMMX) stock earlier this year, a positive sign for shareholders (Simply Wall St.) +19.12%
Mar-07-22 08:00AM	Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022 (GlobeNewswire) -10.90%
Feb-22-22 08:00AM	ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease (GlobeNewswire) -9.50%
Feb-01-22 11:36AM	5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI (InvestorPlace) +13.55%
09:30AM	ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022 (GlobeNewswire)
Jan-31-22 08:00AM	ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data (GlobeNewswire)
Jan-25-22 12:17PM	Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies (Benzinga)
10:15AM	IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale (GlobeNewswire)
Jan-19-22 08:00AM	ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles (GlobeNewswire)
Jan-12-22 08:43AM	Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study (Benzinga) +18.42%
08:00AM	ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study (GlobeNewswire)
Jan-06-22 09:00AM	Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders (GlobeNewswire) -18.67%

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hsu Jason	Director	Dec 11 '23	Buy	4.67	31,000	144,894	813,000	Dec 12 06:25 PM
Hsu Jason	Director	Dec 08 '23	Buy	4.88	25,000	122,025	782,000	Dec 12 06:25 PM
Hsu Jason	Director	Sep 15 '23	Buy	2.49	7,000	17,396	757,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 14 '23	Buy	2.58	10,000	25,772	750,000	Sep 18 07:03 PM
Ng Carey	Director	Sep 14 '23	Buy	2.58	10,000	25,760	10,000	Sep 15 06:27 PM
Hsu Jason	Director	Sep 12 '23	Buy	2.83	30,000	84,864	740,000	Sep 18 07:03 PM
Adams Helen C.	Director	Sep 12 '23	Buy	2.96	13,000	38,492	13,000	Sep 14 05:20 PM
Hsu Jason	Director	Sep 11 '23	Buy	2.89	25,000	72,280	710,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 08 '23	Buy	2.53	10,000	25,317	685,000	Sep 12 04:58 PM
BUCHAN MELISSA JANE	Director	Sep 07 '23	Buy	2.46	20,000	49,226	20,000	Sep 11 05:18 PM
Marquet Magda	Director	Sep 06 '23	Buy	2.47	9,000	22,213	20,000	Sep 08 05:46 PM
Marquet Magda	Director	Sep 05 '23	Buy	2.47	10,000	24,722	11,000	Sep 06 04:33 PM
Marquet Magda	Director	Aug 31 '23	Buy	2.01	1,000	2,010	1,000	Sep 05 06:43 PM

Open in Screener

ARCT

Arcturus Therapeutics Holdings Inc

May 01 • 04:00PM ET

27.91

Dollar change +2.34
Percentage change 9.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ARCT Arcturus Therapeutics Holdings Inc daily Stock Chart

Held by: ARKG VTI IWM VXF IWN IBB DFAT LABU AVUV SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.04	Insider Own	8.75%	Shs Outstand	26.83M	Perf Week	3.45%
Market Cap	751.34M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	-1.30%	Shs Float	24.56M	Perf Month	-13.38%
Income	-26.59M	PEG	-	EPS next Q	-1.23	Inst Own	93.43%	Short Float	18.78%	Perf Quarter	-15.35%
Sales	160.88M	P/S	4.67	EPS this Y	-162.18%	Inst Trans	-0.12%	Short Ratio	9.43	Perf Half Y	49.57%
Book/sh	10.38	P/B	2.69	EPS next Y	93.03%	ROA	-6.04%	Short Interest	4.61M	Perf Year	6.85%
Cash/sh	12.89	P/C	2.17	EPS next 5Y	-	ROE	-9.69%	52W Range	17.52 - 43.81	Perf YTD	-11.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.40%	ROI	-8.73%	52W High	-36.29%	Beta	2.65
Dividend TTM	-	Quick Ratio	4.72	Sales past 5Y	310.16%	Gross Margin	-	52W Low	59.30%	ATR (14)	1.84
Dividend Ex-Date	-	Current Ratio	4.72	EPS Y/Y TTM	-395.33%	Oper. Margin	-4.30%	RSI (14)	44.15	Volatility	5.73% 6.37%
Employees	180	Debt/Eq	0.11	Sales Y/Y TTM	-21.90%	Profit Margin	-16.53%	Recom	1.30	Target Price	67.62
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-107.43%	Payout	-	Rel Volume	1.92	Prev Close	25.57
Sales Surprise	-10.23%	EPS Surprise	67.75%	Sales Q/Q	-82.40%	Earnings	May 08 AMC	Avg Volume	489.43K	Price	27.91
SMA20	-3.59%	SMA50	-16.34%	SMA200	-6.49%	Trades		Volume	939,753	Change	9.15%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Canaccord Genuity	Buy	$90
Jul-24-23	Initiated	William Blair	Outperform	$71
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy	$19 → $51
Nov-14-22	Resumed	Wells Fargo	Overweight	$35
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform	$18
Nov-03-22	Upgrade	Citigroup	Neutral → Buy	$22 → $35
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight	$16 → $25
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight	$86 → $39
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral	$21 → $18
Apr-21-22	Downgrade	Citigroup	Buy → Neutral	$86 → $29
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell	$29
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform	$31
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight	$71
Jun-25-21	Resumed	Goldman	Neutral	$29
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight	$33 → $25
Jun-04-21	Resumed	Robert W. Baird	Neutral	$31
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell

Show Previous Ratings

Today 10:01AM	Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for (Zacks) +9.15%
Apr-25-24 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 (Business Wire)
Mar-28-24 01:34AM	Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares (GuruFocus.com)
Mar-22-24 01:26AM	Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ... (GuruFocus.com)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
12:10PM	Loading…
Mar-08-24 12:10PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:54AM	Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:42PM	Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments (GuruFocus.com)
05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:21PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress (Business Wire)
Mar-04-24 01:23PM	Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why (Zacks) -5.24%
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +9.41%
09:00AM	Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-22-24 08:30AM	Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis (Business Wire) +6.12%
01:04PM	Loading…
Feb-21-24 01:04PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 (InvestorPlace)
Feb-20-24 04:39PM	3 Tech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
09:00AM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 (Business Wire)
Feb-05-24 08:30AM	New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster (PR Newswire)
Jan-23-24 04:16AM	18 High Growth Low PE Stocks (Insider Monkey)
Jan-05-24 01:17PM	PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems (PR Newswire)
Dec-21-23 08:00AM	CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster (Business Wire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-13-23 10:39PM	3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 (InvestorPlace) +11.18%
Dec-08-23 10:13AM	12 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Dec-04-23 08:30AM	Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-28-23 08:05AM	Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults (PR Newswire)
07:56AM	Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up (Zacks)
Nov-27-23 08:30AM	Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis (Business Wire) +7.90%
Nov-15-23 01:26PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Call Transcript (Insider Monkey) +16.08%
11:30AM	Loading…
11:30AM	Q3 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 05:19PM	Arcturus Therapeutics Holdings Inc (ARCT) Reports Significant Revenue Growth in Q3 2023 (GuruFocus.com) +9.54%
04:13PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
10:56AM	The 3 Most Undervalued Biotech Stocks to Buy: November 2023 (InvestorPlace)
Oct-25-23 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 (Business Wire)
Oct-23-23 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire)
Oct-04-23 11:01PM	Insider Sell: Pad Chivukula Sells 5,000 Shares of Arcturus Therapeutics Holdings Inc (GuruFocus.com)
08:30AM	Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government (Business Wire)
Sep-26-23 08:30AM	Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis (Business Wire)
Sep-19-23 08:30AM	Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants (Business Wire)
Sep-05-23 08:30AM	Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19 (Business Wire)
Aug-17-23 08:30AM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Aug-14-23 09:00AM	Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government (Business Wire) +6.37%
Aug-10-23 07:15AM	New Strong Sell Stocks for August 10th (Zacks)
Aug-08-23 02:39PM	Why Shares of Arcturus Therapeutics Dropped on Tuesday (Motley Fool) -19.22%
01:09PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Call Transcript (Insider Monkey)
08:43AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
07:39AM	Q2 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 07:50PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:43PM	Arcturus Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
Aug-04-23 09:21AM	4 Biotech Stocks Set to Outpace Q2 Earnings Estimates (Zacks)
Jul-28-23 05:14PM	3 Biotech Stocks to Buy Before the Breakout (InvestorPlace)
Jul-24-23 04:01PM	Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023 (Business Wire) +5.38%
Jul-18-23 06:22AM	3 Biotech Stocks for Getting Rich in 2023 (InvestorPlace)
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jul-14-23 02:36PM	Biotech, Cboe Rally To New Highs, Top Buy Points (Investor's Business Daily) +15.03%
Jul-05-23 06:15AM	Calculating The Intrinsic Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) (Simply Wall St.)
Jun-14-23 08:24AM	Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholder returns have been stellar, earning 225% in 5 years (Simply Wall St.)
Jun-01-23 08:30AM	Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency (Business Wire)
May-18-23 07:16AM	Growth Investors: Industry Analysts Just Upgraded Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Revenue Forecasts By 76% (Simply Wall St.)
May-12-23 02:04AM	4 big analyst picks: Albemarle scores fresh Overweight rating (Investing.com) -5.50%
May-09-23 05:35PM	Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates (Zacks)
04:37PM	Arcturus Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
09:29AM	12 Best Fast Growth Stocks to Buy Now (Insider Monkey)
May-08-23 07:43AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? (Simply Wall St.) +5.24%
Apr-28-23 01:39PM	12 Best Fast Growth Stocks to Buy Now (Insider Monkey)
Apr-26-23 08:30AM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023 (Business Wire) -5.09%
Apr-17-23 07:10AM	Why Investors Shouldn't Be Surprised By Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 79% Share Price Surge (Simply Wall St.)
Mar-30-23 08:29AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 11:45AM	Why Arcturus Therapeutics Stock Is Soaring Today (Motley Fool) +30.13%
Mar-28-23 05:15PM	Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress (Business Wire)
Mar-27-23 09:11AM	Market Sentiment Around Loss-Making Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) (Simply Wall St.)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-07-23 08:00AM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 (Business Wire)
Feb-06-23 08:30AM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Jan-31-23 08:30AM	Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis (Business Wire)
Dec-28-22 11:35AM	Swelling losses haven't held back gains for Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders since they're up 109% over 5 years (Simply Wall St.)
Dec-19-22 08:30AM	Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) -7.04%
Dec-13-22 08:30AM	Arcturus Appoints John Markels, Ph.D. to its Board of Directors (Business Wire) +7.29%
Dec-12-22 08:30AM	CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics (PR Newswire)
Dec-01-22 10:23AM	The Founder of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), Joseph Payne, Just Bought A Few More Shares (Simply Wall St.)
Nov-16-22 05:24AM	These Analysts Just Made A Significant Downgrade To Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) EPS Forecasts (Simply Wall St.)
Nov-12-22 07:04AM	Arcturus Therapeutics Holdings Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-09-22 05:25PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.58%
04:01PM	Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress (Business Wire)
Nov-07-22 05:00PM	Arcturus Therapeutics to Present at the Following Investor Conferences in November (Business Wire)
Nov-04-22 05:46AM	Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains? (Zacks) +6.22%
Nov-02-22 12:00PM	Why Arcturus Therapeutics Stock Is Skyrocketing Today (Motley Fool) +18.65%
07:43AM	Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines (Benzinga)
Nov-01-22 06:05PM	Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines (Business Wire)
06:00PM	CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology (PR Newswire)
08:55AM	Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-26-22 04:30PM	Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022 (Business Wire)
Oct-18-22 08:05AM	When Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Become Profitable? (Simply Wall St.)
Sep-27-22 06:00PM	Arcturus Therapeutics to Attend the Following Investor Conferences (Business Wire) +8.51%
Sep-22-22 12:28PM	7 Small-Cap Stocks to Buy on the Dip or Youll Be Kicking Yourself Later (InvestorPlace)

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chivukula Pad	Chief Scientific Officer & COO	Mar 25 '24	Sale	35.02	17,435	610,574	473,448	Mar 27 04:15 PM
Chivukula Pad	Chief Scientific Officer & COO	Mar 19 '24	Sale	35.01	8,565	299,839	490,883	Mar 21 05:27 PM
Chivukula Pad	Chief Scientific Officer & COO	Nov 01 '23	Sale	18.72	5,000	93,602	499,448	Nov 03 04:30 PM
Chivukula Pad	Chief Scientific Officer & COO	Oct 02 '23	Sale	25.61	5,000	128,062	504,448	Oct 04 04:06 PM
Chivukula Pad	Chief Scientific Officer & COO	Sep 01 '23	Sale	31.45	5,000	157,264	509,448	Sep 05 04:05 PM
Chivukula Pad	Chief Scientific Officer & COO	Aug 01 '23	Sale	34.91	5,000	174,550	514,448	Aug 03 04:15 PM
Kummerfeld Keith C	See Remarks	Jul 14 '23	Option Exercise	8.96	6,968	62,408	7,918	Jul 18 06:50 PM
Chivukula Pad	Chief Scientific Officer & COO	Jul 14 '23	Sale	35.01	25,000	875,250	519,448	Jul 18 06:50 PM
Kummerfeld Keith C	See Remarks	Jul 14 '23	Sale	35.00	6,968	243,880	950	Jul 18 06:50 PM
Chivukula Pad	Chief Scientific Officer & COO	Jul 03 '23	Sale	28.75	5,000	143,750	544,448	Jul 07 06:01 AM
Chivukula Pad	Chief Scientific Officer & COO	Jun 01 '23	Sale	27.16	5,000	135,800	549,448	Jun 05 04:07 PM
Chivukula Pad	Chief Scientific Officer & COO	May 11 '23	Sale	30.24	7,925	239,652	554,448	May 12 04:05 PM
Chivukula Pad	Chief Scientific Officer & COO	May 10 '23	Sale	30.00	17,075	512,250	562,373	May 12 04:05 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

IMMX

Immix Biopharma Inc

ARCT

Arcturus Therapeutics Holdings Inc

Upgrade your FINVIZ experience